Close Menu

NEW YORK – Interpace Diagnostics reported this morning that its second quarter revenues rose 14 percent year over year, primarily due to the expansion of its existing products in the gastroenterological and endocrine space. 

For the three months ended June 30, the Parsippany, New Jersey-based firm reported revenues of $6.3 million, up from $5.5 million in the year-ago quarter but missing the consensus Wall Street estimate of $6.6 million. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.